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PPRECLINICAL STUDY
Potentiation of Doxorubicin
Cardiotoxicity by Iron Loading in a Rodent Model
Gurusher S. Panjrath, MD,* Virender Patel, MD,* Carolina I. Valdiviezo, MD,‡ Navneet Narula, MD,†
Jagat Narula, MD, PHD, FACC,* Diwakar Jain, MD, FACC*
Philadelphia, Pennsylvania; and New York, New York
Objectives The role of iron toward doxorubicin (DOX) cardiotoxicity was studied using a rodent model of dietary carbonyl
iron loading.
Background Doxorubicin, a commonly used anticancer drug, is known to cause serious and potentially life-threatening cardio-
toxicity. Doxorubicin cardiotoxicity is thought to be mediated through free-radical injury.
Methods Male Sprague Dawley rats fed iron-rich chow (n  8) and regular chow (n  8) were treated with DOX or saline
(4 animals in each arm). Cardiotoxicity was assessed using mortality, weight changes, Tc-99m annexin-V imag-
ing, histopathology, and immunohistochemistry.
Results Animals fed iron-rich chow showed significantly higher DOX cardiotoxicity as evidenced by greater weight loss
(107  14 g vs. 55  10 g weight loss, p  0.05), higher annexin uptake (0.14  0.01% vs. 0.08  0.01% in-
jected dose/g of myocardium, p  0.05), more severe myocyte injury on electron microscopy, and significantly
higher cleaved caspase-3 staining compared with regular chow fed rats given DOX. Feeding iron-rich chow alone
did not result in any cardiotoxicity.
Conclusions Dietary iron loading resulted in a substantially increased DOX cardiotoxicity in rats. Body iron stores as well as
its bioavailability in tissue may be important independent predictors of susceptibility to DOX cardiotoxicity in
man. Further clinical studies are warranted. (J Am Coll Cardiol 2007;49:2457–64) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.060m
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A
roxorubicin (DOX), a potent anthracycline antineoplastic
gent, is used widely in a variety of malignancies and tumors
1–3). Despite being one of the most effective anticancer
gents, its use is limited by serious and sometimes life-
hreatening cardiotoxicity (4,5). Despite extensive studies in
nimals and cell culture models, the exact cellular, biochem-
cal, molecular, and genetic mechanism of DOX cardiotox-
city is not fully known. Advanced age, concomitant treat-
ent with radiation therapy, or high-dose cyclophosphamide
nd pre-existing heart disease have been identified as predis-
osing factors for DOX cardiotoxicity (4,6). However, these
actors alone cannot explain the wide variation in individual
usceptibility to DOX cardiotoxicity.
Redox injury and interference with protein synthesis are
onsidered to play a significant role in DOX cardiotoxicity
7–9). Conditions that exacerbate free-radical formation
rom the *Division of Cardiology, Drexel University College of Medicine, Philadel-
hia, Pennsylvania; †Pathology Department, University of Pennsylvania, Philadel-
hia, Pennsylvania; and the ‡Cardiovascular Biology Research Laboratory, Mount
inai School of Medicine, New York, New York. Supported by the American Society
f Nuclear Cardiology/Fujisawa Healthcare Award, Bethesda, Maryland.d
Manuscript received December 4, 2006; revised manuscript received January 24,
007, accepted February 6, 2007.ay enhance DOX cardiotoxicity. Various studies have
roposed a role of metallic ions in DOX-mediated damage
10–12). Doxorubicin interacts with metallic ions, especially
ron, which results in the formation of DOX-iron (III)
omplex (13–15). Iron independently plays an important role
n generation of harmful free radicals with potential deleterious
ffects on the myocardium. Iron chelator dexrazoxane is rec-
mmended for use in patients receiving higher doses of DOX
o prevent heart failure (16,17). Despite these measures,
ardiotoxicity continues to be an important limiting factor
or DOX therapy.
We have aimed to elucidate the role of iron in potentia-
ion of DOX-induced cardiotoxicity. We hypothesize that
levated body iron content enhances the cardiotoxic effects
f DOX. We used an in-vivo rodent model of nutritional
ron loading, which may simulate patterns of higher body
ron stores observed in patients undergoing cancer
hemotherapy.
ethods
nimals. Male Sprague Dawley rats (Charles River Labo-
atories, Wilmington, Massachusetts) were used in accor-
ance with guidelines on animal care. The study was
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imal care committee. The ani-
mals received a single intrave-
nous dose of DOX. Further
division was based on those fed
regular rat chow or those fed
ron-rich chow. Each group had a corresponding saline-
reated control. Figure 1 demonstrates the various study
roups. There were 4 animals in each of the 4 study groups.
pilot group of 5 animals was initially tested for dosage and
as not included for hypothesis testing.
ietary iron loading. Animals age 6 weeks were fed with
odified AIN-76A purified rodent chow with 10,000 ppm
1%) Carbonyl Iron (Dyets Inc., Bethlehem, Pennsylvania)
or 10 weeks at Gwathmey Inc. (Cambridge, Massachu-
etts) before being shipped to our animal facility. Serum
ron levels were periodically checked. Before drug adminis-
ration, serum levels of iron-loaded animals were 2-fold
igher (423 g/dl vs. 187 g/dl) compared with those in
egular chow group. Hepatic iron content was measured in
animals in both the regular chow as well as the iron-rich
how fed group. Up to 7-fold elevation (2,397 g/g vs.
12 g/g dry weight) in hepatic iron level was observed in
ron-loaded animals. This model of dietary carbonyl iron
verload is commonly used in experimental work and is
nown to result in up to 2-fold increase in serum iron and
- to 8-fold increase in hepatic tissue iron over a period of
2 to 16 weeks (18–20). Increased iron content is seen in
iver, spleen, heart, intestinal mucosa, and pancreas, but this
oes not result in liver cirrhosis (18).
After acclimatization, animals were randomized into
reatment groups. Iron-rich diet was maintained throughout
he course of the study.
xperimental protocol. DOX TREATMENT. A pilot group
n 5) of regular chow fed rats was given a single 12 mg/kg
ody weight intravenous dose of DOX. All animals died
ithin 9 days. Therefore, the dose was scaled down to a
ingle dose of 6 mg/kg. Iron-rich chow fed rats (16  2
eeks old) and regular chow fed rats (14  2 weeks old)
ere given a single intravenous dose of DOX (6 mg/kg) or
Abbreviations
and Acronyms
DOX  doxorubicin
HFE  iron regulatory gene
Figure 1 Experimental Protocol
Four animals were included in each
experimental as well as control group. DOX  doxorubicin.baline in their tail veins. Animals were anesthetized 2 to 3
eeks later for imaging, blood sampling, and tissue harvest-
ng (Fig. 1). A mixture of xylazine (10 mg/kg) and ketamine
80 mg/kg) was used at 0.1 ml/100 g (1:10 dilution) of body
eight intraperitoneally for anesthesia.
echnetium-99m annexin imaging. Human recombinant
nnexin-V produced by expression in Escherichia coli (Apo-
ate, Theseus, Boston, Massachusetts), derivatized with
ydrazinonicotinamide (HYNIC, Anor Med, Langley,
ritish Columbia, Canada), and radiolabeled with
echnetium-99m (99mTc) (1.0 to 1.2 mCi) (21) was injected
n tail veins. Rats were anesthetized 3 h after injection of
9mTc annexin-V and placed directly on the collimator of a
amma camera (Vertex, Philips Inc., Milipitas, California).
lanar whole body images were obtained in prone position
sing an energy window of 140 20% KeV for 20 min. The
mages were analyzed visually for the intensity of radiotracer
ptake in the hearts. After imaging, the rats were eutha-
ized. Excised hearts were imaged by laying directly on the
amma camera. The hearts were then segmented into 4
egions: apical, subapical, midventricular, and basal. These
egments were weighed and counted in an automatic well-
ype gamma counter for determination of the percent
njected dose of 99mTc annexin-V.
erial body weight, survival, and gross appearance. Body
eight was monitored at baseline and twice a week until the
nd of the study. General appearances of animals, move-
ent, feeding, social interaction, posture, dehydration, and
ur quality were monitored.
The animals that became moribund, lost 20% of body
eight compared with baseline body weight, and stopped
eeding during the course of experiment and were unlikely
o survive for more than 1 day had to be euthanized early
sing a large intraperitoneal dose of pentobarbital.
etermination of myocardial iron content. Myocardial
ron content was measured for all animals using acid
igestion of myocardial tissue samples followed by iron
uantification with atomic spectroscopy (Kansas State Uni-
ersity Veterinary Laboratory).
istopathology and immunohistochemistry. LIGHT MI-
ROSCOPY. Cross sections of heart were cut, fixed in
uffered 4% formaldehyde, paraffin embedded, sectioned at
to 4 m, and stained with hematoxylin and eosin and
russian blue.
ISTOCHEMISTRY. Sections were stained for activated
aspase-3 (Biocare Medical, 1:50, Walnut Creek, Califor-
ia) (22). Sections were deparaffinized, blocked with 3%
ydrogen peroxide, treated with 1% bovine serum albumin
n phosphate-buffered saline, and incubated with the pri-
ary antibody at 37°C for 2 h. The specimens were then
ncubated with horseradish peroxidase-cojugated streptavi-
in (Biogenex, San Ramon, California) for 10 min and
eveloped with 3,3’diaminobenzidine (Biogenex), and
ounterstained with hematoxylin. Grading was performed
y a blinded reader based on distribution. We created a
s
d
t
6
E
h
2
d
w
l
c
S
(
S
a
c
a
R
A
a
I
a
o
D
i
w
o
f
t
a
w
(
o
D
i
w
D
w
a
a
w
f
e
9
w
c
s
c
v
c
a
a
a
M
i
p
g
M
t

H
n
r
c
t
P
g
w
b
c
7
o
m
s
t
D
F
s
p
I
a
d
2459JACC Vol. 49, No. 25, 2007 Panjrath et al.
June 26, 2007:2457–64 Iron in Doxorubicin Cardiotoxicitycoring system ranging from 0 to 2. Scoring based on
istribution was graded on extent of area involved. Less
han 30% area involvement was given a score of 0, 30% to
0% a score of 1, and more than 60% was scored as 2.
LECTRON MICROSCOPY. Small pieces of heart were fixed in
alf Karnovsky’s fixative containing 2.5% glutaraldehyde and
% paraformaldehyde in 0.1 M phosphate buffer and embed-
ed in epoxy resin, and 40- and 90-nm thick sections were cut
ith an ultramicrotome, double stained with uranyl acetate and
ead citrate, and examined using a transmission electron mi-
roscope (Hitachi H-600, Gaithersburg, Maryland).
TATISTICAL ANALYSIS. SPSS/PC 11.0 software was used
SPSS Inc., Chicago, Illinois). Results are expressed in mean
EM. Nonparametric tests including Kruskal-Wallis 1-way
nalysis of variance and Mann-Whitney U test were used to
ompare continuous variables and chi-square for discrete vari-
bles. P values 0.05 were considered significant.
esults
ll saline-treated control animals survived with normal growth
nd weight gain with no signs of functional impairment.
ron-rich chow fed, saline-treated group. Iron-rich chow
lone did not result in any deleterious effects with no signs
f distress, normal growth, and 100% survival.
OX treatment in regular chow fed group. Single large
ntravenous dose of DOX (12 mg/kg) resulted in death
ithin 10 days in all animals (n 5). Animals showed signs
f distress, decreased movement, hunched posture, fuzzy
ur, appearance of dark halos around their eyes, and cessa-
ion of feeding. Based upon this, 6-mg/kg dose was used in
ll subsequent single-dose groups. This resulted in a 16%
eight loss over 3 weeks compared with 22% weight gain
p  0.05) in corresponding saline-treated control animals
ver 3 weeks (Fig. 1).
OX treatment in rats fed iron-rich chow. Six-mg/kg
ntravenous dose of DOX resulted in a significant and rapid
eight loss (18%) over 2 weeks whereas the corresponding
OX-treated animals in regular chow fed group lost 16%
eight while both saline-treated control groups fed regular
nd iron-rich chow gained weight (Fig. 2). Since these
nimals lost 18% body weight compared with baseline
ithin 2 weeks of receiving DOX and developed severe
unctional impairment, they had to be sacrificed 1 week
arlier than planned.
9mTc annexin-V imaging. No 99mTc annexin-V uptake
as observed in cardiac regions of regular chow or iron-rich
how fed control groups. Intense cardiac uptake was ob-
erved in all DOX-treated groups (Fig. 3). Quantitative
ardiac uptake analysis from ex-vivo gamma counting re-
ealed only a minimal uptake in regular chow and iron-rich
how fed animals (Fig. 4). Doxorubicin-treated groups had
significantly higher myocardial uptake. Iron-rich chow fed
nimals treated with DOX had the highest uptake of 99mTc
nnexin-V in cardiac tissue. gyocardial iron content. Feeding iron-rich chow resulted
n only a slight increase in myocardial iron content com-
ared with the regular chow fed animals in saline-treated
roups (59.00 4.56 g/g vs. 48.33 7.88 g/g, pNS).
yocardial iron contents in the corresponding DOX-
reated groups were 70.00  3.08 g/g vs. 52.25  3.63
g/g, p  0.02) (23) (Fig. 5).
istopathology. On light microscopy, no changes were
oticed in any group (Fig. 6). Hematoxylin and eosin was
emarkably negative for any abnormality. Only rare nonspe-
ific focal inflammatory infiltrates were seen in both DOX-
reated regular chow fed and iron-rich chow fed groups. On
russian blue staining, no stainable iron was seen in any
roup indicating that increase in myocardial iron content
ith feeding iron-rich chow was relatively small and well
elow the levels seen in pathological iron storage conditions.
Electron microscopy showed no cardiac injury in regular
how or iron-rich chow fed control animals (Figs. 7A and
B). Doxorubicin-treated animal groups had varying grades
f injury. Regular chow fed animals showed lesser degree of
yofilament loss with DOX treatment (Fig. 7C). More
evere changes were seen in iron-rich chow fed animals
reated with DOX. Iron-rich chow animals treated with
OX dose had a greater extent of myocyte injury (Fig. 7D).
requent areas of myofibrillar degeneration and loss, de-
truction of myocytes, along with mitochondrial and sarco-
lasmic swelling and destruction were seen in this group.
mmunohistochemical analysis. Immunostaining using
ntibodies specific for activated caspase-3 (Fig. 8) revealed
istinct positive reaction in all DOX-treated animals. In the
Figure 2 Weight Change
Both iron-rich chow and regular chow fed control animals gained weight. Regu-
lar chow fed animals treated with doxorubicin (DOX) showed a progressive
weight loss. Weight loss in iron-rich chow group treated with DOX was signifi-
cantly higher compared with that in other groups.roup fed regular chow, positive reaction for caspase-3 was
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Iron in Doxorubicin Cardiotoxicity June 26, 2007:2457–64eaker and focal (grade 1). Animals fed iron-rich chow had
more intense and widespread positive reaction for acti-
ated caspase-3 (grade 2). No staining was observed in
ontrol animals that received saline, with and without
ron-rich chow (grade 0).
Figure 3 99mTc Annexin-V Imaging
Planar whole body (top) and ex-vivo images of heart (bottom) of animals from eac
and spleen (S) with variable uptake in the heart (arrows). No myocardial uptake s
with doxorubicin (DOX) show intense cardiac uptake (C and D).
Figure 4 Percent ID/g of Myocardial 99mTc Annexin-V Uptake
Highest uptake in iron-rich chow fed animals
treated with doxorubicin (DOX). ID  injected dose.iscussion
e employed a rodent model for studying DOX cardiotox-
city and its interaction with iron loading by feeding
ron-rich chow for 10 to 14 weeks. Feeding iron-rich chow
group on 99mTc annexin-V imaging. There is intense Annexin uptake in liver (L)
control group (A and B). Regular chow and iron-rich chow fed animals treated
Figure 5 Myocardial Iron
A mild increase in myocardial iron content is seen in iron-rich chow fed animals
in both control and doxorubicin (DOX)-treated groups. *p  0.05 compared
with DOX and saline.h sub
een in
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June 26, 2007:2457–64 Iron in Doxorubicin Cardiotoxicityesulted in a profound increase in DOX cardiotoxicity.
hese animals lost greater body weight. There was greater
yocardial 99mTc annexin uptake in iron-rich chow fed
OX-treated animals compared with that in regular chow
ed animals treated with DOX. These findings were con-
rmed by diffuse and more intense staining of activated
aspase-3 on myocardial specimens of iron-rich chow fed
nimals on DOX treatment. Activated caspase-3 is a sen-
itive early marker for apoptosis (24). Iron-rich chow alone
id not result in any toxicity as seen by effect on body
eight, 99mTc annexin uptake, and absence of signs of
njury on histopathological analysis. Light microscopy did
ot reveal any obvious abnormality among the various
roups. This is consistent with previous observations where
outine light microscopy was not found to be helpful in
etecting or grading the severity of DOX cardiotoxicity
25). Electron microscopy showed most intense degenera-
ive changes in iron-fed DOX-treated animals (Fig 7).
We used 99mTc annexin-V imaging and activated
aspase-3 for studying the intensity of myocardial toxicity in
ats. 99mTc annexin-V imaging has been used for studying
ther forms of myocardial injury including myocardial
nfarctions, cardiac transplant rejections (26), and inflam-
atory myocardial diseases (27). Radiolabeled annexin-V
Figure 6 Light Microscopy
Light microscopy of hematoxylin- and eosin-stained myocardial tissue shows no sig
(B) iron-rich chow fed animals treated with saline, (C) regular chow fed animals trinds to phosphatidylserine, a phospholipid normally iresent only in inner leaflet of cell membrane that gets
xposed on outer cell membrane leaflet in cells undergoing
poptosis. Higher uptake of annexin-V was seen in iron-
ich chow fed animals treated with DOX, compared with
hat seen in regular chow fed animals given DOX.
Mammalian hearts share a susceptibility to DOX cardio-
oxicity due to limited protective mechanism from oxidative
njury. Heart tissue is relatively deficient in catalase, which,
long with glutathione peroxidase, forms the defense against
edox injury. The heart primarily depends on glutathione
eroxidase to protect itself from free-radical injury. Doxo-
ubicin interferes with glutathione peroxidase making the
eart more susceptible to redox injury (28). Doxorubicin-
ron complex can catalyze the transfer of electrons from
educed glutathione to molecular oxygen to generate highly
eactive superoxide, hydrogen peroxide, and hydroxyl radi-
als (29).
A number of animal models including mice, rats, dogs,
wine, hamsters, and rabbits have been used for studying
OX cardiotoxicity (30,31). We used a rat model because
f its suitability for imaging studies and for ease with which
utritional iron overload can be induced in this species. As
entioned earlier, iron overload can be produced by paren-
eral administration of iron or by feeding chow fortified with
myocyte injury in (A) regular chow fed animals treated with saline,
with DOX, and (D) iron-rich chow fed animals treated with doxorubicin (DOX).ns of
eatedron salts or elemental iron (e.g., carbonyl iron). Parenteral
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Iron in Doxorubicin Cardiotoxicity June 26, 2007:2457–64ron loading results in massive tissue iron overload, with
ultiorgan damage and toxicity, while oral feeding results
nly in a relatively modest increase in body iron content
ithout overt signs of end-organ damage. Carbonyl iron is
etter absorbed and results in less gastrointestinal and
ystemic toxicity compared with ionic iron (32,33). Dietary
arbonyl iron may result in pattern of iron overload similar
o that of subclinical iron overload in man. Whereas this
ild increase in myocardial iron in saline-treated animals
id not result in any obvious cardiotoxicity, this was
ssociated with marked increase in myocyte injury in DOX-
reated animals.
To the best of our knowledge, this is the first study to
mploy a rat model of dietary carbonyl iron overload to
ssess DOX cardiotoxicity. Doxorubicin cardiotoxicity has
een under investigation in humans for well over 3 decades.
Figure 7 Electron Microscopy
(A) No loss of myofilaments is seen in regular chow fed saline-treated animal. (B)
chow fed doxorubicin-treated animal showed infrequent areas of myofilament loss
(arrow) seen in iron-rich chow fed animals treated with doxorubicin. Iron-rich chow
loss (arrow) accompanied by swelling of sarcoplasmic reticulum, which are characnumber of variables have been considered as contributors to DOX cardiotoxicity (6). Even while iron has been
eported to play a role in DOX cardiotoxicity in experimen-
al studies (13,34,35), importance of iron as an independent
ariable has not been studied in humans. A wide variation
an occur in body iron stores in patients undergoing cancer
hemotherapy, depending upon abnormal blood losses,
lood transfusions, iron supplementation, and nutritional
tatus. Adult and pediatric patients undergoing treatment
or leukemia and other malignancies can develop a signifi-
ant level of iron overload during and as a result of
hemotherapy and bone marrow transplantation (36). It has
lso been observed that iron level may predict outcomes in
ancer survivors. Level of iron overload observed varies
etween moderate to severe levels in 15% to 20% of
ong-term survivors (37–39). Several common genetic dis-
rders may also influence body iron stores. Hemochroma-
al myofilament loss in iron-rich chow fed animal treated with saline. (C) Regular
) without any sarcoplasmic swelling. (D) Larger areas of myofilament loss
imals treated with doxorubicin show frequent and large areas of myofilament
c changes seen in doxorubicin cardiotoxicity. N  nucleus.Minim
(arrow
fed an
teristiosis, the most common form of genetic disorder of iron
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June 26, 2007:2457–64 Iron in Doxorubicin Cardiotoxicityverload, has a frequency of 1:250 to 400 in Americans of
orthern European descent. This is characterized by ho-
ozygous mutation (C282Y/) of iron regulatory gene
HFE gene) resulting in unregulated intestinal absorption of
ron. However, heterozygous prevalence of this gene
C282Y/) is very common in the same population (7% to
%) (40). Another mutation of the HFE gene associated
ith milder degree of iron overload (H63D/) has a
revalence of up to 20% (40). Heterozygous carriers of these
utations may have subclinical and otherwise asymptomatic
ncrease in body iron stores. Dexrazoxane, the only chelator
sed clinically in patients, is recommended for use beyond a
umulative DOX dose of 300 mg/m2 (17). As toxicity may
egin much earlier, in the presence of elevated body iron,
erhaps this agent may be considered earlier during the
ourse of DOX or even before DOX therapy in those with
levated body iron stores.
Our findings are similar to those of Miranda et al. (41)
ho recently observed increased susceptibility to DOX
ardiotoxicity in HFE knockout mice. They observed
igher mortality, greater increase in creatine kinase and
Figure 8 Activated Caspase-3 Immunohistochemistry of Myoca
Activated caspase-3 was present in the cytoplasm of cells with morphology consis
doxorubicin (C and D). No staining is seen in control animals fed (A) regular chow
greater area of staining involving higher number of myocytes compared with regulaminotransferase enzymes, and more severe histologic rhange in the HFE knockout mice compared with that in
ild type. Both of these studies emphasize the critical role
f iron in DOX cardiotoxicity. However, Corna et al. (42)
eported a paradoxical benefit between anthracycline-
erived reactive oxygen species, increased ferritin synthesis,
nd resistance to iron-mediated damage. Authors reported
rotection of H9c2 cells from ferric ammonium citrate-
nduced damage on pretreatment with DOX by down-
egulating iron regulatory protein-2 and subsequent increase
n ferritin synthesis. The role of iron and reactive oxygen
pecies in anthracycline-induced cardiotoxicity may, there-
ore, be more complex than previously believed (42). How-
ver, these findings need further study and are contrary to our
ndings of increased cardiac injury in iron-supplemented
nimals receiving DOX.
We speculate that higher body iron stores in patients who
ave received multiple blood transfusions, prolonged iron
upplementation, or those with unsuspected HFE muta-
ions may be predisposed to DOX cardiotoxicity. Prospec-
ive clinical studies are needed to test our hypothesis. If
hese results are confirmed by clinical studies, simple and
Specimens
ith apoptosis. Positive staining is seen in myocardium of animals treated with
) iron-rich chow. Iron-rich chow fed animals treated with doxorubicin (D) show a
fed animals treated with doxorubicin (C).rdial
tent w
or (B
r chowelatively inexpensive screening tests for total body iron
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Iron in Doxorubicin Cardiotoxicity June 26, 2007:2457–64tores and presence of HFE mutation can be used to screen
atients before initiating DOX chemotherapy.
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